Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest ScinoPharm Taiwan Ltd. Stories

2014-02-14 00:21:19

TAINAN, Feb. 14, 2014 /PRNewswire/ -- ScinoPharm (TWSE:1789) an active pharmaceutical ingredient (API) specialty company, announced unaudited record results for its fiscal year 2013. The company posted a historically high NT$5.088 billion (US$167.6 million) in revenue, up 11% over 2012's record-breaking numbers with after-tax net profits of NT$1.273 billion (US$42.4 million), an increase of 9% compared to the same period in 2012. Profits were also at record highs. After-tax earnings...

2013-12-12 00:22:33

TAINAN, Dec. 12, 2013 /PRNewswire/ -- ScinoPharm (TWSE:1789) today announced that the company has completed construction of its Changshu plant on a 16-acre (6.5-hectare) site. The facilities, located in Changshu, (Jiangsu province) China, include an R&D process development center and a multipurpose API (active pharmaceutical ingredients) manufacturing plant fully compliant with U.S., EU, and Chinese CGMP standards. A total of US$113 million was invested in this facility. The new...

2013-11-11 00:21:13

TAINAN, Nov. 11, 2013 /PRNewswire/ -- Genovate Biotechnology Co. Ltd. (4130:TT) and ScinoPharm Taiwan Ltd. (1789:TT) announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity. The new-generation oral...

2013-09-09 04:21:19

TAINAN, Sept. 9, 2013 /PRNewswire/ -- ScinoPharm Taiwan Ltd. (TSE: 1789.TW) announced that its Tainan, Taiwan Facility provides commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for Trokendi XR(TM), a novel once-daily extended release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals in the U.S. market. Supernus received approval to market Trokendi XR(TM) by the United States...

2013-08-07 04:21:10

TAINAN, Aug. 7, 2013 /PRNewswire/ -- ScinoPharm (Changshu) Pharmaceuticals and Sundia MediTech Company Ltd. announced today a strategic alliance to seek more opportunities for collaboration on Contract Research and Manufacturing Services (CRAMS) in mainland China and to tap into this large and growing business potential. Dr. Jo Shen, CEO of ScinoPharm Taiwan and Chairman of ScinoPharm Changshu, stated, "Resources from our Changshu site in Jiangsu province, China, and the...

2013-05-10 04:21:35

TAINAN, Taiwan, May 10, 2013 /PRNewswire/ -- ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active Pharmaceutical Ingredients (APIs) have been initially selected for development and future sales as injectable formulation products from the list of ScinoPharm-developed APIs. This will allow the companies to compete within the...

2013-01-30 04:21:07

TAINAN, Taiwan, Jan. 30, 2013 /PRNewswire/ -- ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, Inc. (Foresee) jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the...

2012-07-18 18:20:40

TAINAN, Taiwan, July 18, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia(TM), a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012. Qsymia(TM) is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese or...

2012-06-28 22:20:44

TAINAN, Taiwan, June 29, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that it will invest NT$1.13 billion (approximately US$37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company's premise at the Tainan Science Park. ScinoPharm, a global leader in supplying oncological APIs for injectable products, currently has the most number of oncological APIs for the generic industry....

2011-02-08 01:00:00

TAINAN, Taiwan, Feb. 8, 2011 /PRNewswire-Asia/ -- ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd(TM), a new drug entity recently approved by the United States Food and Drug Administration. Viibryd is a novel...